MaxCyte targets $30M to $32M revenue in 2026 following strategic acquisitions and platform launches. The biotech company completed integration of SeQure DX and launched its ExPERT DTx platform during 2025, positioning itself for growth in the coming year. CEO Maher Masoud characterized 2025 as challenging but marked by meaningful progress, with the company making significant operational changes to support its expansion. The revenue guidance reflects management confidence in upcoming milestones and market adoption of its new technologies. Investors are monitoring whether the company can execute on these projections and achieve profitability as it scales operations in the competitive cell therapy market.
Post from MarketNews_en
Log in to interact with content.